Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > To the longs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Feb 18, 2021 5:41pm
251 Views
Post# 32604889

RE:RE:RE:To the longs

RE:RE:RE:To the longs
crow27 wrote: I agree Mugs, This was very high risk investment for everyone without a clear path for phase 3. Sure we got some dilution but what company does not have to bite the bullet at times. 
I think most got twisted because we hit the $7's and thought it would keep going. This deal and the Nuance deal has taken so much risk out of the equation. It makes ATB stronger in dealing with other partners and BiG Pharma also. This is far from a fly by the seat of your pants company.
We would have all liked this deal to happen at $10.00 but be thankful it was at $6 and the warrants at $7.50. 
Dan is playing it safe and smart and this will increase the share price. We can now do a steadty uninterupted march towards $15.00.
Can you imagine another partner or two coming on board? Flush with cash and full steam ahead.


Yes - and that dilution has an ability to create magnified value in this arena.

Imagine a company that just went to market after having its revenue destroyed by COVID (following one of those).  Which one would you rather be a part of ?  Obviously tthis company.

We are not going to care about this diluti9on in a lttle while (IMO).


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities